Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate versus sevelamer hydrochloride in haemodialysis patients with ESRD-related hyperphosphataemia
2004-001608-11Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hyperphosphatemia and end-stage kidney disease (ESKD) comparing Lanthanum carbonate with Sevelamer hydrochloride (2 arms). Primary endpoints: Serum phosphate reduction and Serum phosphate control rate. Started Mar 2005; status: completed.
02
Drugs
lanthanum carbonatesevelamer carbonate
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2004-001608-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001608-11.